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IMPORTANCE A new statistical approach is needed to describe the clinical differences
between type I and type II Usher syndrome and between the 2most frequent mutations in
the USH2A gene.
OBJECTIVES To describe the primary phenotypic characteristics and differences between
type I and type II Usher syndrome and to establish a phenotype-genotype correlation for the
2most frequent mutations in the USH2A gene.
DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study at a genetics department, in
which clinical evaluations were performed for 433 patients (297 unrelated families) who were
classified as having type I, II, III, atypical, or unclassified Usher syndrome according to their
clinical history, pedigree data, results from ophthalmological studies, and audiological,
neurophysiological, and vestibular test results. Molecular studies were performed for 304
patients (256 unrelated families). TheMann-Whitney U test or the χ2 test was used for
calculating the differences betweenmean values for the analyzed parameters.
MAIN OUTCOMES ANDMEASURES Age at diagnosis; age at onset of night blindness, visual field
loss, visual acuity loss, and cataracts; and severity and age at diagnosis of hearing loss.
RESULTS The comparison between patients with type I Usher syndrome and those with type
II Usher syndrome revealed P < .001 for most items analyzed. Themost frequent mutations in
the USH2A gene were the p.Glu767Serfs*21 and p.Cys759Phemutations, with an allelic
frequency of 23.2% (63 of 272 alleles) and 8.1% (22 of 272 alleles), respectively. The
phenotypic analysis for patients carrying p.Cys759Phe showed P < .001 for most items
analyzed when compared with patients carrying p.Glu767Serfs*21 and when compared with
patients carrying other mutations in the USH2A gene. None of the p.Cys759Phe patients
exhibited a severe hearing loss phenotype, andmore than 60% had only mild hearing loss.
Most patients carrying the p.Glu767Serfs*21 mutation (72.1%) were moderately deaf.
CONCLUSIONS AND RELEVANCE Our study presents the clinical differences between type I and
type II Usher syndrome and between the 2most frequent mutations in the USH2A gene.
Detailed genotype-phenotype correlations, as presented in our study, allow for a better
correlation of clinical signs with a known genotype and can improve the clinical management,
genetic counseling, and risk assessment of patients with Usher syndrome because an
estimated prognosis of their disease can bemade.
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U sher syndrome isanautosomal recessivedisorderwitha prevalence of 3.2 to 6.2 cases per 100 000 people.1-3It is characterized by sensorineural hearing loss, reti-
nitis pigmentosa (RP), and variable vestibular dysfunction.
Ushersyndromeisclinicallyandgeneticallyheterogeneousand
is themost common form of genetic deafness and blindness,
representing 50% of all cases.4
Themajority of patientswithUsher syndromeusually fall
into 1 of 3 clinical categories.5 Type I Usher syndrome is the
most severe form and is characterized by severe to profound
congenital deafness, vestibular areflexia, andprepubertal on-
set ofRP; type IIUsher syndromemanifests asmoderate to se-
vere hearing loss, absence of vestibular dysfunction, and sub-
sequent onset of RP; and type III Usher syndrome is
characterized by progressive postlingual hearing loss, vari-
able onset of RP, and variable vestibular response. However,
some cases are not easily classifiable under these categories
and could be categorized as atypical Usher syndrome.6,7
To date, 10 genes responsible for Usher syndrome have
been identified: 6 genes responsible for type I Usher syn-
drome (MYO7A,USH1C,CDH23,PCDH15,USH1G, andCIB2); 3
genes responsible for type II Usher syndrome (USH2A,GPR98
[also known as VLGR1], and DFNB31 [orWHRN]; and 1 gene
responsible for type III Usher syndrome (USH3AorCLRN1),8,9
although theHARSgenehasbeen recentlyproposedas anovel
gene responsible for type IIIUsher syndrome.10Another gene,
PDZD7,was shown to contribute to type IIUsher syndromeby
modifying the retinal phenotype on a USH2A background or
in digenic inheritance with GPR98.11
With the exception of some inbred populations, in which
1 or 2mutations account for most of the syndromic cases (eg,
p.Tyr173* in the CLRN1 gene in Finns; c.733C>T, p.Arg245* in
thePCDH15gene inAshkenazi Jews;andc.216G>AintheUSH1C
gene in Acadians),12-14 most of the mutations responsible for
Usher syndrome are private and are found in 1 or a few fami-
lies. Only the mutation c.2299delG (p.Glu767Serfs*21) on the
USH2A gene accounts for a high proportion of cases of type II
Usher syndromeof Europeanoriginwith allele frequencies of
15% to 50%,15 aswell asmutation c.2276C>G (p.Phe759Cys) on
theUSH2Agene,which is implicated ina4%ofmutatedalleles
in autosomal recessive RP in Spanish patients.16
Although theauditoryandvestibular functionsare thedis-
tinguishing features of the different types of Usher syn-
drome,RP is themainophthalmicmanifestation sharedby all
the types of Usher syndrome. Some authors1,17-20 have re-
ported an earlier onset and more severe form of RP in pa-
tients with type I Usher syndrome. However, it is uncertain
whether these differences are highly prevalent or clearly dis-
tinguishableamongthedifferent typesofUsher syndrome,and
some authors21-25 have argued that the prognosis for visual
function is not significantly different in the 2 most prevalent
types (type I and type II Usher syndrome).
To date, many genetic advances have been made in the
molecular diagnosis of Usher syndrome. However, the indis-
tinguishable symptoms within the same clinical type of
Usher syndrome and the similar symptoms among the dif-
ferent clinical types of Usher syndrome hamper this molecu-
lar diagnostic.
In the present study, we evaluated 433 patients (belong-
ing to 297 unrelated families) who received a diagnosis of
Usher syndrome. Of these 433 patients, 304 patients (256
families) underwent molecular analysis. Our aim was to
quantitatively describe the primary phenotypic characteris-
tics and differences between type I and type II Usher syn-
drome in this cohort and to establish a phenotype-genotype
correlation for the most frequent mutations in the USH2A
gene. This information would be useful in determining the
prognosis for affected patients and would assist in genetic
counseling and in assigning phenotypes for molecular
study.
Methods
Audiological, Vestibular, and Ophthalmological Studies
A total of 297 unrelated families (433 patients) that were sus-
pected of having Usher syndrome presented to our genetics
department during the period from 1992 to 2012. Written in-
formed consent was obtained from all patients and family
members. All procedureswere reviewed and approvedby the
ethics committee of the hospital and adhered to the tenets of
the Declaration of Helsinki (59th World Medical Association
General Assembly; Seoul, Korea; October 2008).
Patients were classified according to their clinical history,
pedigreedata, results fromophthalmological studies,18-20,25 au-
diological test results17,24,25 (or self-reportedhearing loss), and
neurophysiological and vestibular test results.17,24,25 Based on
all this information, all patients were assigned to 1 of the fol-
lowing4groups: type I, type II, type III, andatypicalUsher syn-
drome;when the available datawere not sufficient for clinical
classification, patientswere assigned to theunclassifiedUsher
syndromegroup.Ophthalmological datawereavailable for 193
patients with type II Usher syndrome, 57 patients with type I
Usher syndrome, and 39 patients with atypical Usher syn-
drome (for a total of 289 patients).
To facilitate the comprehension of the USH2A screening
results, we divided those patients with mutations in USH2A
into 3 categories: category 1 consists of all patients presenting
with 1 or 2 mutated alleles in the USH2A gene (including pa-
tientswith type II, atypical, or unclassifiedUsher syndrome);
category2consistsofpatientswith type IIUsher syndromepre-
senting with at least 1 mutated allele in the USH2A gene; and
category 3 consists of all patients with type II Usher syn-
drome, regardless of whether or not a mutated allele was
detected.
Ophthalmological statuswasestablishedaccording todata
obtained following an established protocol. These data con-
sisted of the patient’s own ophthalmological history and the
ophthalmological history of his or her family (eg, onset of
symptoms,ageatdiagnosis, anddiagnosis)obtained fromoph-
thalmological studies,18-20,25 including (at least) assessmentof
night blindness, progressive loss of peripheral vision (com-
puterized central and peripheral visual-field testing), best-
corrected visual acuity, fundus compatible with RP26,27 (oph-
thalmoscopic examination after pupillary dilation), and
electrophysiological examinationwith pathologic electroret-
Research Original Investigation Usher Syndrome and the USH2AGene
158 JAMAOphthalmology February 2015 Volume 133, Number 2 (Reprinted) jamaophthalmology.com
Copyright 2015 American Medical Association. All rights reserved.
inogram showing a marked reduction in rod or rod and cone
signal28 (full-field electroretinogram according to the stan-
dards of the International Society for Clinical Electrophysiol-
ogy of Vision [http://www.iscev.org]).
Dataonhearing losswereavailable for213patientswithtype
IIUsher syndrome,75patientswith type IUshersyndrome,and
24patientswith atypical Usher syndrome (for a total of 312 pa-
tients). Hearing loss severity was established according to au-
diological tests,17,24,25andpatientswereclassifiedashavingmild
(between>25and≤40dB),moderate (between>40and≤70dB),
or severe/profound (>70 dB) hearing loss.
Genetic Analysis
Atotalof433patients (belonging to297unrelated families)who
receivedadiagnosis ofUsher syndromewereevaluated for ge-
netic study.At least 1 affected familymember fromeachof 256
recruited families underwentmolecular testing (eTable in the
Supplement). Only 129 patients (from 41 unrelated families)
were not analyzed owing to different causes (eg, a molecular
diagnosis had alreadybeengiven to an affected sibling or data
on DNAwere not available) (eTable in the Supplement).
Patients were analyzed using a specific Usher syndrome
genotyping microarray for mutation screening (http://www
.asperbio.com/asper-ophthalmics/usher-syndrome-genetic
-testing)28 (versions fromOctober2007 toDecember2012).The
Usher syndromemicroarraydetectsat least 1mutation inabout
34%ofthepatientsbecauseitonlydetectsthosepreviouslyiden-
tified mutations that have been incorporated into the
microarray,29,30 followedbySangerdirect sequencingofUsher
syndrome genes for confirmation of mutations found on the
microarray (MYO7A3 1 [NM_000260.3], CDH2332 ,33
[NM_022124.5], PCDH1534,35 [NM_033056.3], USH1C36
[NM_005709.3], USH1G37 [NM_173477.2], USH2A7,38
[NM_206933.2], GPR9839 [NM_032119.3], DFNB3139
[NM_015404.3], andCLRN140 [NM_046380.1]). Segregation (in
all cases in which it was possible) and complete sequencing
of the gene, if only 1 mutation was found in that gene, were
performed.
Othermolecularanalyses includedcurrentlyavailablecom-
mercial multiplex ligation-dependent probe amplification
(MLPA) assays for Usher syndrome (the SALSA MLPA [MRC-
Holland] P361-A1/P362-A2 and P292-A2 probe mixes) and the
direct sequencingof genes in selected cases according to apri-
oritization algorithm.41 Genetic variants were classified as
clearly pathological, UV4 (unclassified variant [UV] likely
pathogenic), UV3 (UV of uncertain pathogenicity), UV2 (UV
likelynonpathogenic),UV1 (UV likelyneutral), andclearlyneu-
tral according to the Leiden Open Variation Database (https:
//grenada.lumc.nl/LOVD2/Usher_montpellier/index.php).42
Statistical Analysis
The statistical analysis of the differences between mean val-
ueswas calculated for thedifferent parameters analyzed. The
Mann-WhitneyU test included in SPSS version 15.0 (SPSS Inc)
wasusedtocalculate thedifferences in theonsetofnightblind-
ness, visual field loss, and visual acuity loss and in the age at
diagnosis of cataracts and of hearing loss because these vari-
ables did not present a normal distribution. The differences
in severity of hearing loss were analyzed using a χ2 test in-
cluded in Epidat 4.0.
Results
As shown in the eTable in the Supplement, 61.2% (95% CI,
55.7%-66.7%) of the analyzed patients (186 of 304) carried at
least 1 mutated allele in 1 Usher syndrome gene: 45 patients
with type I Usher syndrome, 114 patients with type II Usher
syndrome, 25 patients with atypical Usher syndrome, 1 pa-
tientwith type III Usher syndrome, and 1 patientwith unclas-
sified Usher syndrome (changes classified as neutral, UV1, or
UV2 have not been taken into account). The number and per-
centage of patients classified according to the clinical sub-
type and genotype, and their molecular characterization, are
shown in the eTable in the Supplement.
Thecomparisonsbetween the type I and type IIUsher syn-
dromephenotypes revealedP < .001 formostof the itemsana-
lyzed and P = .02 for the age at onset of visual acuity loss
(Table 1). Theonly analyzed itemthatdidnot showP < .05was
age at diagnosis of cataracts (P = .20). Themean (SD) age at di-
agnosis, age at onset of night blindness, age at onset of visual
field loss, age at onset of visual acuity loss, age at diagnosis of
cataracts, andage atdiagnosis of hearing loss for patientswith
type I or type II Usher syndrome are shown in Table 1.
Data on severity of hearing loss among patientswith type
I or type II Usher syndrome are shown in eFigure 1 in the
Supplement; all patients with type I Usher syndrome (except
1 patient who reported moderate hearing loss) had severe to
profound hearing loss (98.7% [95% CI, 97.4%-100.0%]),
whereas patients with type II Usher syndrome hadmoderate
hearing loss (80.3% [95% CI, 75.0%-85.6%]). The statistical
analysis showedP < .001 for the comparisonof the severity of
Table 1. Clinical Data (Ocular and Audiological Symptoms) for PatientsWith Type I or Type II Usher Syndrome
Data
Type I Usher Syndrome Type II Usher Syndrome
P Valuea
Patients
Analyzed, No.
Age, Mean
(SD), y
Patients
Analyzed, No.
Age, Mean
(SD), y
Diagnosis of disease 53 15.6 (10.4) 180 26.8 (11.4) <.001
Onset of NB 55 9.5 (8) 187 18.1 (9.7) <.001
Onset of VF loss 59 11.2 (8.1) 193 21.8 (11.2) <.001
Onset of VA loss 37 19.1 (15.9) 140 25.7 (13.5) .001
Diagnosis of cataracts 27 33.4 (13) 110 37 (13.2) .10
Diagnosis of hearing loss 72 1.1 (0.5) 194 9.2 (11) <.001
Abbreviations: NB, night blindness;
VA, visual acuity; VF, visual field.
a Determined by use of the
Mann-Whitney U test.
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hearing loss betweenpatientswith type IUsher syndromeand
patients with type II Usher syndrome.
Regarding the USH2A phenotype, 112 of 114 molecularly
characterized patients with type II Usher syndrome (98.2%
[95%CI, 95.8%-100.0%]) carriedat least 1mutatedallele in the
USH2A gene; a similar percentage was found for 23 of 25 mo-
lecularly characterized patients with atypical Usher syn-
drome (92.0% [95% CI, 81.4%-00.0%). The clinical diagnosis
received by patientswho carried at least 1USH2Amutated al-
lele was type I or atypical Usher syndrome, except for 1 of the
patients with unclassified Usher syndrome who was homo-
zygous for USH2A (c.2299delG; p.Glu767Serfs*21) (Table 2).
Among the 136 USH2Amutated cases (including cases of
type II, atypical, and unclassified Usher syndrome), we de-
tected 76.1% (95% CI, 71.0%-81.2%) of the expected muta-
tions (category 1; 207 of 272 alleles) (Table 3). Also, we found
thatUSH2A accounted for 76.3% (95%CI, 70.8%-81.9%) of the
mutated alleles in those cases of type II Usher syndromewith
at least 1 detectedmutation (category 2: 171 of 224 alleles) and
for 45.5% (95%CI, 40.4%-50.5%)of the total type IIUsher syn-
drome alleles included in our study (category 3: 171 of 376
alleles).
Themost frequentmutationwasp.Glu767Serfs*21,which
accounted for 23.2% (95% CI, 18.1%-28.2%), 25.5% (95% CI,
19.7%-31.2%), and 15.2% (95%CI, 11.5%-18.8%) for category 1,
category 2, and category 3, respectively (Table 3). The
p.Cys759Phemutationaccountedfor8.1%(95%CI,4.8%-11.3%)
for category 1, 4%(95%CI, 1.4%-6.6%) for category 2, and2.4%
(95%CI,0.8%-3.9%) for category3 (Table3).The restof themu-
tations in USH2A accounted for less than 5% in all categories
(Table3).Thephenotypesassociatedwithp.Glu767Serfs*21and
p.Cys759Phemutations are shown in Table 4.
Patients carrying mutations in the USH2A gene (patients
with type II or atypicalUsher syndrome; clinical datawerenot
available for the patient with unclassified Usher syndrome)
were divided into 3 groups for phenotype analysis: the
p.Glu767Serfs*21 group (those with at least 1 allele with the
p.Glu767Serfs*21mutation), thep.Cys759Phegroup(thosewith
at least 1 allele with the p.Cys759Phe mutation), and “other”
group (thosewhodidnothaveeither thep.Glu767Serfs*21mu-
tation or the p.Cys759Phe mutation).
Patientscarryingat least 1mutatedallelewithp.Cys759Phe
hadeither the type IIUsher syndromephenotype (40.9%[95%
CI, 20.4%-61.4%]) or the atypical Usher syndromephenotype
(59.1% [95% CI, 38.6%-79.6%]). The p.Glu767Serfs*21 muta-
tion in theUSH2A gene showed a positive predictive value of
90.4% for the type II Usher syndrome phenotype, inmolecu-
larly characterized patients presenting with at least 1 mu-
tated allele in the USH2A gene.
Themean (SD) ageatdiagnosis, ageatonsetofnightblind-
ness, age at onset of visual field loss, age at onset of visual acu-
ity loss, age at diagnosis of cataracts, and age at onset of hear-
ing loss forp.Glu767Serfs*21,p.Cys759Phe,and“other”patients
are shown in Table 5. The comparison between groups
p.Glu767Serfs*21 and “other” showed P > .05 for all analyzed
parameters (data not shown). The mean values for the
p.Glu767Serfs*21 groupwerevery similar to those found in the
general type II Usher syndrome group (Tables 1 and 5). The
analysis of p.Cys759Phe vs p.Glu767Serfs*21 revealed P < .01
formostof theophthalmological itemsanalyzed (Table5),with
p.Cys759Phe showing amilder ophthalmological phenotype.
Although most of the patients carrying the p.Cys759Phe
mutation had only mild hearing loss, and none of them had
the severehearing loss phenotype,most patients carrying the
p.Glu767Serfs*21mutationweremoderately deaf (72.1% [95%
CI, 58.7%-85.5%]). Data on the severity of hearing loss among
patients withUSH2Amutations are shown in eFigure 2 in the
Supplement.Thecomparisonof theseverityofhearing lossbe-
tween p.Glu767Serfs*21 and p.Cys759Phe patients resulted in
P < .001, and the comparisonof the severityofhearing lossbe-
tween “other” and p.Cys759Phe patients resulted in P < .001.
No difference was found in the severity of hearing loss be-
tweenp.Glu767Serfs*21 and“other”patients (datanot shown).
Discussion
ClinicaldifferencesbetweentheUshersyndromesubtypeswere
establishedlongago.1,5Nevertheless, it isnotalwayseasytoclas-
sify patients under any single subtype.6 In our analysis, it has
been observed that all visual impairment in patientswith type
I Usher syndrome (except cataracts) appears at around adoles-
cence,whereas forpatientswith type IIUshersyndrome,symp-
toms are diagnosed in the third decade of life (Table 1). Hear-
ing loss in patientswith type I Usher syndrome is diagnosed in
the first yearof life,whereas forpatientswith type IIUsher syn-
drome,themeanageatdiagnosisofhearing loss is9years.These
phenotypicdifferencescanhelpnotonlywith regard to the ini-
Table 2. Clinical Diagnosis for PatientsWithMutations in theUSH2AGene
Type of Usher Syndrome, Mutation Patients,a No.
Type II
p.Glu767Serfs*21 47
p.Cys759Phe 9
Other 56
Total 112b
Atypical
p.Glu767Serfs*21 4c
p.Cys759Phe 10
Other 9
Total 23d
Unclassified
p.Glu767Serfs*21 1e
Total 136f
a These patients underwent molecular testing and presented with at least 1
mutated allele.
bOne allele was detected in 53 patients, and 2 alleles were detected in 59
patients.
c Double heterozygous patients (p.Glu767Serfs*21 and p.Cys759Phe) have been
included in the p.Glu767Serfs*21 group.
dOne allele was detected in 12 patients, and 2 alleles were detected in 11
patients.
e Two alleles were detected.
f One allele was detected in 65 patients, and 2 alleles were detected in 70
patients.
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tial clinical classificationbutwith regard to themolecular study
approach, because vestibular data are not always available for
all patients and because clinical data can be incomplete for all
the items needed for classification.
Wemust keep inmind that all items analyzed, except for
type I Usher syndromehearing loss, have a variable age at on-
set in both type I and type II Usher syndrome groups. How-
ever, given that all the phenotypic variables analyzed showed
statistical differences between type I and type II Usher syn-
drome (with the exception of cataracts), we can say that the
onset of clinical symptoms (visual and audiological impair-
ment)occurs later inpatientswith type IIUsher syndromethan
inpatientswith type IUsher syndrome.Moreover,hearing loss
in patients with type II Usher syndrome is said to be
prelingual,17,43 although diagnosis (or awareness by patients)
is usually postlingual.44 This could be due to various reasons,
such as conversational frequencies that canbeonlymildly af-
fected in these patients44 (patientsmay not be aware of hear-
ing loss), very slow progression of hearing impairment (re-
ported by some patients), and/or damaging environmental
agents that can worsen hearing loss (reaching a level of im-
pairment that the patient can notice).
When analyzing the phenotype associatedwith themost
frequentmutations in theUSH2A gene, we found that an evi-
dent difference appears between p.Glu767Serfs*21 and
p.Cys759Phe. The p.Glu767Serfs*21 groupmean values for all
Table 3. Results Among the 136USH2AGeneMutated Cases Regarding Allelic Frequency for theUSH2AGene’sMost FrequentMutationsa
Mutation(s)
USH2A Gene
Mutated
Alleles, No.
Global Allelic Frequency
of USH2A Among Patients With
Usher Syndrome
(Category 1)
Allelic Frequency of USH2A
Among Patients With Type II
Usher Syndrome and Mutation
(Category 2)
Among 188 Patients With
Type II Usher Syndrome Who
Underwent Molecular Testing
(Category 3)
%
(95% CI) No./Total No.
%
(95% CI) No./Total No.
%
(95% CI) No./Total No.
c.2299delG, p.Glu767Serfs*21 63 23.2
(18.1-28.2)
63/272 25.5
(19.7-31.2)
57/224 15.2
(11.5-18.8)
57/376
c.2276C>G, p.Cys759Phe 22 8.1
(4.8-11.3)
22/272 4
(1.4-6.6)
9/224 2.4
(0.8-3.9)
9/376
c.9799 t > C, p.Cys3267Arg 13 4.8
(2.2-7.3)
13/272 5.4
(2.4-8.3)
12/224 3.2
(1.4-5.0)
12/376
c.5776 + 1G>A 8 2.9
(0.9-4.9)
8/272 3.4
(1.1-6.0)
8/224 2.1
(0.7-3.6)
8/376
c.10273_10274dupTT,
p.Cys3425Phefs*4
8 2.9
(0.9-4.9)
8/272 3.1
(0.8-5.4)
7/224 1.9
(0.5-3.2)
7/376
c.2431_2432delAA, p.Lys811Aspfs*11 7 2.6
(0.7-4.5)
7/272 1.8
(0.1-3.5)
4/224 1.1
(0.0-2.1)
4/376
c.10712C>T, p.Thr3571Met 6 2.2
(0.5-4.0)
6/272 2.7
(0.6-4.8)
6/224 1.6
(0.3-2.9)
6/376
c.1841-2A>G, p.Gly614Aspfs*6 5 1.8
(0.2-3.4)
5/272 2.2
(0.3-4.2)
5/224 1.3
(0.2-2.5)
5/376
Otherb 75 27.6
(22.3-32.9)
75/272 28.1
(22.2-34.0)
63/224 16.6
(13.0-20.5)
63/376
Total 207 76.16
(71.0-81.2)
207/272 76.3
(70.8-81.9)
171/224 45.5
(40.4-50.5)
171/376
a To facilitate the comprehension of the USH2A screening results, we divided
those patients with mutations in USH2A into 3 categories: category 1 consists
of all patients presenting with 1 or 2 mutated alleles in the USH2A gene
(including patients with type II, atypical, or unclassified Usher syndrome);
category 2 consists of patients with type II Usher syndrome presenting with at
least 1 mutated allele in the USH2A gene; and category 3 consists of all patients
with type II Usher syndrome, regardless of whether or not a mutated allele
was detected.
b Less than 5mutations.
Table 4.USH2AGene p.Glu767Serfs*21 and p.Cys759PheMutations: Associated Phenotypesa,b
Frequent Mutations in USH2A
Patients With Type II Usher
Syndrome
Patients With Atypical Usher
Syndrome
Molecular
Study
Phenotype
Analysis
Molecular
Study
Phenotype
Analysis
p.Glu767Serfs*21/p.Glu767Serfs*21 10 10 0 0
p.Glu767Serfs*21/otherc 15 14 0 0
p.Glu767Serfs*21/unknown 22 20 1 1
p.Glu767Serfs*21/p.Cys759Phe 3 3
c.2299delG, p.Glu767Serfs*21, No./Total No.
(% [95% CI]) of patients
47/51 (92.2
[84.8-99.5])
46 4 (7.8
[0.5-15.2])
4
p.Cys759Phe/otherc 5 5 5 5
p.Cys759Phe/unknown 4 3 5 5
p.Cys759Phe, No./Total No. (% [95% CI])
of patients
9/22 (40.9
[20.4-61.4])
8 13 (59.1
[79.6-38.6])
13
a Data are No. of patients, unless
otherwise indicated.
b The patient with unclassified Usher
syndromewhowas homozygous for
the c.2299delG (p.Glu767Serfs*21)
mutation has not been included.
c Patients with a different mutation at
p.Glu767Serfs*21 or p.Cys759Phe
for the secondmutated allele are
referred to as “other” patients.
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analyzed signs are very similar to themeanvalues for the total
number of patients with type II Usher syndrome and for pa-
tients carrying other mutations of USH2A other than
p.Cys759Phe (eFigure2 in theSupplement;Tables 1and4).This
observation is expected because p.Glu767Serfs*21 is themost
frequent mutation found in our patients with type II Usher
syndrome.
With regard to the p.Glu767Serfs*21 allele,we have found
a global frequency for patients with type II Usher syndrome
(15.2% [95% CI, 11.6%-18.8%]) that is similar to those previ-
ously reported in our population.15,45 To our knowledge, this
is the first work comparing the phenotypic differences, both
audiological and ophthalmological, between carriers of
p.Glu767Serfs*21 and carriers of p.Cys759Phe.
Thep.Glu767Serfs*21mutationwaspresent in92.2% (95%
CI, 84.8%-99.5%) of patients who received a clinical diagno-
sis of type II Usher syndrome but only in 7.8% (95% CI, 0.5%-
15.2%) of patients who received a clinical diagnosis of atypi-
cal Usher syndrome. On the other hand, the p.Cys759Phe
mutationwas present in 40.9% (95%CI 20.4-61.4) of patients
with type II Usher syndrome and 59.1% (95% CI 38.6-79.6) of
patientswith atypicalUsher syndrome.Thep.Cys759Phemu-
tation was initially reported to cause autosomal recessive RP
withouthearing impairment.46Ourgroupandothers7,16,42,46-48
haveshownthatcompoundheterozygotesofp.Cys759Phewith
other USH2Amutations can cause autosomal recessive RP or
type II Usher syndrome.
We did not find the p.Cys759Phe mutation in the homo-
zygous state in our cohort of patients with type II Usher syn-
drome.However, according to our data, those compoundhet-
erozygotes carryingp.Cys759Pheappear todisplay anatypical
type II Usher syndrome phenotype.
The phenotype of patients with type II Usher syndrome
whocarry thep.Cys759Phemutation is characterizedbya later
onset of RP, compared with the general population of pa-
tientswith type IIUsher syndrome, andmild tomoderate (but
not severe) hearing loss. These facts can explain the late di-
agnosis of some patients with Usher syndromewho received
an unclear diagnosis because hearing loss can be overlooked
or can be diagnosed later (being interpreted as presbyacusis).
In addition, variability in sensorineural hearing loss for
p.Cys759Phe has already been described.7,38
According to our data, patients with RP who carrying
p.Cys759Pheshouldundergoanaudiological examination (and
follow-up) byanexpert, todiscardor correctlydiagnoseUsher
syndrome, because a correct diagnosis has substantial impli-
cations for hearing prognosis and clinical management, and
also for genetic counseling and family risk. Usher syndrome
isaclinicallyandgeneticallyheterogeneousdisease.Our study
presents, in an objective way, the clinical differences be-
tween type I and type II Usher syndrome and between the 2
most frequent USH2A gene mutations.
Conclusions
Manyeffortshavebeenmadeto improvetheclinicalandgenetic
diagnosisofUsher syndromebecause thecorrect classification
of patients ashaving type I, type II, or type IIIUsher syndrome
is avery important issuenotonly inmolecular genetic studies,
defining thegenetic testingstrategy,but fromaclinicalpointof
view; it is crucial for theprognosis,management, andcounsel-
lingofpatients. Inthefieldofmoleculardiagnosis, theUshersyn-
dromemicroarraywas implementedtodetectmutationsunder-
lyingUshersyndromecases inacost-efficientway, independent
of the clinical type.Moreover, in spiteof its limitations, as only
detectingpreviously identifiedmutations thathavebeen incor-
porated to themicroarray, its lowmutationdetection rate, and
its need for regular updating, themicroarray has proved to be
a good first choice for diagnostic testing for thepast fewyears.
RegardingthecorrectclassificationofUshersyndrome,mo-
lecular geneticdiagnostichas allowed for abetterunderstand-
ingof this complexdisease.However, diagnosis andclassifica-
tion remain difficult for some patients, and a great effort still
needs to bemade in the field of genotype-phenotype correla-
tions.Aspresented inour study,detailedgenotype-phenotype
correlations allow for a better correlationof clinical signswith
a known genotype and can improve the clinicalmanagement
ofUsher syndromebecause thenanestimatedprognosisofdis-
ease can bemade.
Table 5. Clinical Data (Ocular and Audiological Symptoms) for Patients Carrying p.Glu767Serfs*21, p.Cys759Phe, and OtherMutations onUSH2Aa
Data
p.Glu767Serfs*21 p.Cys759Phe Other P Valueb
Mean (SD), y
Patients,
No.
Mean (SD),
y
Patients,
No.
Mean (SD),
y Patients, No.
p.Glu767Serfs*21 vs
p.Cys759Phe
p.Cys759Phe vs
Other
Diagnosis of
disease
25.2 (10.4) 34 35.1 (12.1) 19 24.8 (11.8) 51 .006 .001
Onset of NB 18.4 (9.2) 36 26.3 (11.1) 18 17.9 (10.4) 52 .009 .001
Onset of VF loss 20.4 (9.9) 40 28.2 (11.8) 19 22 (12.8) 55 .02 .01
Onset of VA loss 23.8 (15.2) 23 28.4 (12.8) 14 25.9 (12.4) 39 .20 .60
Diagnosis of
cataracts
34.9 (12.0) 21 48.7 (16.6) 9 34.6 (14.2) 28 .02 .01
Onset of
hearing loss
9.1 (11.0) 42 41.2 (20.0) 1 11.6 (17.6) 54 <.001 <.001
Abbreviations: NB, night blindness; VA, visual acuity; VF, visual field.
a Themutation p.Glu767Serfs*21 is c.2299delG (p.Glu767Serfs*21), and the
mutation p.Cys759Phe is c.2276C>G (p.Cys759Phe), in the USH2A gene.
“Other” refers to patients carrying a mutation in the USH2A gene, but these
patients did not have either the p.Glu767Serfs*21 mutation or the
p.Cys759Phemutation.
bDetermined by use of theMann-Whitney U test.
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A, Morning glory disc anomaly may be associated with ipsilateral carotid dysgenesis andmoyamoya disease (Japanese for the “something hazy like a puff of
cigarette smoke” appearance created by dilated collateral vessels on angiography). Absence of central retinal vasculature gives rise to compensatory
collateralization of chorioretinal anastomoses (cilioretinal vessels) to also impart a “moyamoya” bypass system that is ophthalmoscopically visible within the distal
optic nerve. B, Color Doppler ultrasonography demonstrates the absence of vasculature within the central optic nerve (Video 1 and Video 2). Arterial flowwithin 1
cilioretinal artery is imaged in red.
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